COVID-19: EU Under Pressure To Open Up On Vaccine Costs & Contracts
MEPs Also Want More Clinical Trial Data Published
Executive Summary
Transparency on COVID-19 vaccine funding, pricing and procurement is vital if vaccine hesitancy and disinformation are to be countered, say EU parliamentarians.
You may also be interested in...
EU Bodies Agree Clearer Rules On Joint Procurement Of Vaccines & Treatments
The new regulation on cross-border threats to health is the final part of the European Health Union, along with strengthened roles for the European Medicines Agency and the European Centre for Disease Prevention and Control. Its aim is to ensure collective EU action on preparedness, surveillance, risk assessment, and early warning and response in the event of health emergencies.
EMA Considers EUA-Style Fast Track Decision For Molnupiravir
The European Medicines Agency is considering making a rapid recommendation on MSD’s molnupiravir in order to speed access to the potential ‘game changer’ COVID-19 pill.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.